Investigational drug · Phase 3
DWP16001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetic Nephropathy, T2DM (Type 2 Diabetes Mellitus).
Phase 3Last checked: Nov 19, 2026Latest source record: Jun 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
26
Any phase or sponsor naming "DWP16001"
First trial start
2024
Sep 23, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DWP16001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetic Nephropathy
- T2DM (Type 2 Diabetes Mellitus)
Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "DWP16001" as an intervention, largest first.
- To Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monotherapy in Patients With Type 2 Diabetes MellitusPivotal-lookingNot yet recruiting
Daewoong Pharmaceutical Co. LTD.Industry
NCT07619833 · 510 participants (planned) · Start Jun 2026 · Primary completion Nov 2027
Drug: DWP16001; DWC202518 and 2 more · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Seoul, South Korea
- Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment PatientsPivotal-lookingNot yet recruiting
Daewoong Pharmaceutical Co. LTD.Industry
NCT06606093 · 348 participants (planned) · Start Sep 23, 2024 · Primary completion Sep 1, 2026
Drug: DWP16001 Placebo; DWP16001 0.3mg · For: Type 2 Diabetic Nephropathy
Sites: Ansan, South Korea
- The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on MetforminPivotal-lookingStatus unknown
Daewoong Pharmaceutical Co. LTD.Industry
NCT05505994 · 340 participants · Start Sep 28, 2022 · Primary completion Feb 26, 2024
Drug: DWP16001; Dapagliflozin and 2 more · For: Diabetes Mellitus; Diabetes Mellitus, Type 2; Glucose Metabolism Disorders and 2 more
Sites: Beijing, China
- The Efficacy Nad Safety of DWP16001 Compared to Active Drug in the Treatment of Type 2 Diabetes MellitusPivotal-lookingCompleted
Daewoong Pharmaceutical Co. LTD.Industry
NCT04654390 · 270 participants · Start Dec 30, 2020 · Primary completion Dec 17, 2021
Drug: DWP16001 Amg · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Bucheon-si, South Korea
- A Study to Investigate the Effect of DWP16001 as add-on Therapy to Drug A in Patients With Type 2 Diabetes MellitusPivotal-lookingStatus unknown
Daewoong Pharmaceutical Co. LTD.Industry
NCT05466643 · 240 participants (planned) · Start Mar 17, 2023 · Primary completion Sep 30, 2024
Drug: DWP16001 0.3mg; DWP16001 Placebo · For: Type 2 Diabetes Mellitus
Sites: Seoul, South Korea
- The Efficacy and Safety of DWP16001 in Combination With Metformin in Patients With Type 2 Diabetes.Pivotal-lookingCompleted
Daewoong Pharmaceutical Co. LTD.Industry
NCT04634500 · 200 participants · Start Nov 18, 2020 · Primary completion Nov 3, 2021
Drug: Dapagliflozin · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Soeul, South Korea
- Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes MellitusPivotal-lookingStatus unknown
Daewoong Pharmaceutical Co. LTD.Industry
NCT04014023 · 196 participants (planned) · Start Jul 10, 2019 · Primary completion Mar 2020
Drug: DWP16001; Placebo · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Seoul, South Korea
- Evaluate the Long Term Safety and Efficacy of DWP16001 add-on to Metformin in Patients With T2DM Inadequately Controlled on MetforminPivotal-lookingCompleted
Daewoong Pharmaceutical Co. LTD.Industry
NCT05376969 · 159 participants · Start May 25, 2021 · Primary completion May 16, 2022
Drug: DWP16001 · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Seoul, South Korea
- The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.Pivotal-lookingCompleted
Daewoong Pharmaceutical Co. LTD.Industry
NCT04632862 · 140 participants · Start Nov 11, 2020 · Primary completion Nov 25, 2021
Drug: DWP16001 · For: T2DM (Type 2 Diabetes Mellitus)
Sites: Seoul, South Korea
- Study to Evaluate the Long Term Safety and Efficacy of DWP16001 in Patients With Type 2 Diabetes MellitusPivotal-lookingStatus unknown
Daewoong Pharmaceutical Co. LTD.Industry
NCT06141980 · 134 participants (planned) · Start Dec 2023 · Primary completion Sep 2025
Drug: DWP16001 0.3 mg · For: T2DM (Type 2 Diabetes Mellitus)
Newest research
PubMed records naming it or its code names, newest first.
- Differential glycemic effects of DWP16001 in diabetic dogs according to baseline glycemic status: a multicenter randomized controlled trial.
An JH, Ko BG, Namkung H, et al. · BMC Vet Res 2025
- Effect of the sodium-glucose cotransporter-2 inhibitor, DWP16001, as an add-on therapy to insulin for diabetic dogs: A pilot study.
An JH, Choi HS, Choi JS, et al. · Vet Med Sci 2024
- Combined translational pharmacometrics approach to support the design and conduct of the first-in-human study of DWP16001.
Lee SJ, Bae SH, Jeon S, et al. · Br J Clin Pharmacol 2024
- Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter-2 inhibitor, with phentermine in healthy subjects.
Yoon S, Park MS, Jin BH, et al. · Expert Opin Drug Metab Toxicol 2023
- Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium-glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults.
Jeong SI, Kim Y, Nah JJ, et al. · Br J Clin Pharmacol 2023
- Pharmacokinetic and pharmacodynamic interaction between DWP16001, an sodium-glucose cotransporter 2 inhibitor and metformin in healthy subjects.
Kim B, Huh KY, Hwang JG, et al. · Br J Clin Pharmacol 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.